MAR 29, 2020 1:53 PM PDT

Improving ependymoma diagnostics

Have you ever heard of ependymoma? This rare form of brain cancer most commonly occurs in young children when tumors form from ependymal cells in the brain and spinal cord that line the cerebrospinal fluid passageways. Diagnosing ependymoma is particularly difficult and the medical community is lacking sufficient markers for identifying the disease. But new research published in the journal Autophagy from scientists at Kanazawa University hopes to provide insight that could improve diagnostics and potentially even treatment options.

Researchers Richard Wong and Mitsutoshi Nakada led a team to discover how a gene called TPR is connected to ependymoma. They demonstrated how 38% of ependymoma cases have elevated levels of TPR and investigated whether abnormal TPR levels lead to cancer progression in mice. They found that the TPR gene is vital for the progression of ependymoma tumors.

As Eureka Alert reports, “Deletion of the TPR protein is known to induce a process called autophagy within cells. Autophagy is initiated when a cell is under undue stress and results in the death of damaged cells. The patient tumor samples, with their high levels of TPR protein, showed little or no presence of autophagy. However, autophagy was remarkably high in the mice with TPR depletion. Ependymoma cells were thus spared of autophagic death due to the increased presence of TPR. These damaged cells continued to grow by circumventing the biological systems set up to keep them in check. The high TPR levels were also accompanied by an increase in HSF-1 and MTOR, molecules which are responsible for cell growth and survival.”

These findings provide an opportunity for scientists to target TPR as biomarkers, which can help both in diagnostic assessment and treatment for the cancer. The researchers also determined that inhibiting MTOR would serve in a similar way to treat ependymoma patients.

The authors hope their findings can combine their conclusions to a) help oncologists achieve a more comprehensive diagnosis and b) reduce TPR levels via drugs to limit tumor growth.

Sources: Autophagy, Eureka Alert

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
JUL 22, 2020
Cancer
Investigating a New Target Against Esophageal Cancer
JUL 22, 2020
Investigating a New Target Against Esophageal Cancer
Esophageal cancer remains one of the most dangerous cancers in the world. Most therapies center around chemotherapy, rad ...
JUL 26, 2020
Cancer
Diet confirmed to be linked to prostate cancer risk
JUL 26, 2020
Diet confirmed to be linked to prostate cancer risk
A study published in Nutrients earlier this summer points toward diet as a key risk factor for prostate cancer ...
SEP 02, 2020
Cancer
New contrast dyes detect cancer using tatoo ink
SEP 02, 2020
New contrast dyes detect cancer using tatoo ink
Researchers have developed new cancer detection agents in the form of contrast dyes from tattoo ink. The results of thes ...
SEP 09, 2020
Cancer
Microbubbles enhance delivery of chemotherapy drug
SEP 09, 2020
Microbubbles enhance delivery of chemotherapy drug
New research published in APL Bioengineering reports on a new technology developed by scientists at Tulane Universi ...
SEP 14, 2020
Cancer
We are too uneducated on the risks of colon cancer
SEP 14, 2020
We are too uneducated on the risks of colon cancer
A study conducted by researchers from Florida Atlantic University's Schmidt College of Medicine suggests that too ma ...
SEP 13, 2020
Cancer
Should we be treating kidney cancer differently?
SEP 13, 2020
Should we be treating kidney cancer differently?
New research published in the journal Clinical Cancer Research is questioning how we treat kidney tumors. According ...
Loading Comments...